Investigational drug · Phase 3
Lutetium[177Lu] Oxodotreotide
Also called: dotatate, 177Lu-DOTA0-Tyr3-Octreotate
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
n/a
Any phase or sponsor naming "Lutetium[177Lu] Oxodotreotide"
First trial start
2022
Aug 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Lutetium[177Lu] Oxodotreotide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastroenteropancreatic Neuroendocrine Tumors
- Pheochromocytoma
- Paraganglioma
- Advanced Neuroendocrine Neoplasm
- Neuroendocrine Tumors
Approved drugs for the same conditions: Pancreatic cancer · Brain tumors (glioma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Lutetium[177Lu] Oxodotreotide" as an intervention, largest first.
- A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
NCT05459844 · Phase 3 · Completed · Sinotau Pharmaceutical Group · 196 participants · primary completion Jun 26, 2025
- A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
NCT06398444 · Phase 2/Phase 3 · Recruiting · Sinotau Pharmaceutical Group · 85 participants · primary completion Jun 1, 2027
- Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
NCT04711135 · Phase 2 · Active, not recruiting · Advanced Accelerator Applications · 11 participants · primary completion Mar 12, 2024
Newest research
PubMed records naming it or its code names, newest first.
- Neuroendocrine Neoplasms: Somatostatin Receptor and Fluorodeoxyglucose PET.
Kavanaugh M · Magn Reson Imaging Clin N Am 2027
- Neuroendocrine Theranostics.
Kavanaugh M · Magn Reson Imaging Clin N Am 2027
- Hybrid Imaging in the Head and Neck: Focus on Somatostatin Receptor Imaging-DOTATATE is Great!
Kirsch CFE · Neuroimaging Clin N Am 2027
- Neuro-Oncology: Primary Brain Neoplasms.
Ward RE, Ivanidze J, Barajas RF, et al. · Neuroimaging Clin N Am 2027
- Robotic-assisted transduodenal ampullectomy for a neuroendocrine tumour: A step-by-step surgical video.
Rompianesi G, Fusai GK · Surg Oncol 2026
- A Tale of 3 Tracers: Contrasting Uptake Patterns of 18 F-FDG, 68 Ga-DOTATATE, and 18 F-MFBG in a Pediatric Neuroblastoma Patient.
Si X, Xu Y, Zhang K, et al. · Clin Nucl Med 2026
Also in development for Gastroenteropancreatic Neuroendocrine Tumors
- NP-101Phase 31 trial
Novatek Pharmaceuticals · Gastroenteropancreatic Neuroendocrine Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.